Phase I pharmacological study of intra-arterially infused fotemustine for colorectal liver metastases

European Journal of Cancer

Volumn 34, Issue 1, 1998, Pages 87-91

  Hartmann, J T ^a   Schmoll, E ^b   Bokemeyer, C ^a   Fety, R ^c   Lucas, C ^d   Giroux, B ^d   Schmoll, H J ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Colorectal carcinoma; Fotemustine; Hepatic intra arterial infusion; Nitrosourea derivate; Pharmacokinetics

Indexed keywords

FOTEMUSTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LEUKOPENIA; LIVER METASTASIS; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS;

EID: 0031915240     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00359-6     Document Type: Article

References (9)

1. 1. Brown CE, Warren S. Visceral metastases from rectal carcinoma. Surg Gynecol Obstet 1983, 66, 611-621.
2. 14C-fotemustine in cancer patients. Eur J Cancer 1990, 26, 838-842.
3. 3. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990, 66, 1873-1878.
4. 4. Gordon BH, Richards PR, Hiley MP, et al. A new method for the measurement of nitrosoureas in plasma: an HPLC procedure for the measurement of fotemustine kinetics. Xenobiotica 1989, 19, 329-339.
5. 5. Boutin JA, Norbeck K, Moldeus P. Effects of the new nitrosourea derivate fotemustine on the glutathione reductase activity in rat tissue in vivo and in isolated rate hepatocytes. Eur J Cancer Clin Oncol 1989, 23, 1311-1316.
6. 6. Khayat D, Cour V, Aigner C, et al. A phase II study of hepatic intraarterial fotemustine: final report among 66 evaluable patients. J Cancer Res Clin Oncol 1990, 116, 692.
7. 7. Fetyl R, Lucas C, Solere P, Cour V, Vignoud J. Hepatic intraarterial infusion of fotemustine: pharmacokinetics. Cancer Chemother Pharmacol 1992, 31, 118-122.
8. 8. Iliadis A, Launay-Iliadis MC, Lucas C, et al. Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French cancer centre multicentric study. Eur J Cancer 1996, 32A(3), 455-460.
9. 9. Rougier P, Chabot GG, Bonneterre J, et al. Phase II and pharmacokinetic study of fotemustine in inoperable colorectal cancer [letter]. Eur J Cancer 1993, 29A(2), 288-289.